Tom Verhaeghe

2.0k total citations
76 papers, 1.4k citations indexed

About

Tom Verhaeghe is a scholar working on Molecular Biology, Immunology and Organic Chemistry. According to data from OpenAlex, Tom Verhaeghe has authored 76 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 14 papers in Immunology and 13 papers in Organic Chemistry. Recurrent topics in Tom Verhaeghe's work include Biosimilars and Bioanalytical Methods (13 papers), Chemical synthesis and alkaloids (11 papers) and Pharmacological Effects and Toxicity Studies (8 papers). Tom Verhaeghe is often cited by papers focused on Biosimilars and Bioanalytical Methods (13 papers), Chemical synthesis and alkaloids (11 papers) and Pharmacological Effects and Toxicity Studies (8 papers). Tom Verhaeghe collaborates with scholars based in Belgium, United States and Switzerland. Tom Verhaeghe's co-authors include Tom Desmet, Wim Soetaert, Dirk Aerts, Lieve Dillen, Karel De Winter, Ronald de Vries, Philip Timmerman, Qinying Zhao, Matthias D’hooghe and Rob De Vreese and has published in prestigious journals such as Journal of Biological Chemistry, Angewandte Chemie International Edition and Journal of Clinical Oncology.

In The Last Decade

Tom Verhaeghe

74 papers receiving 1.4k citations

Peers

Tom Verhaeghe
Mark Namchuk United States
Alex Buko United States
Tuomo Laitinen Finland
Naoko Kobayashi Japan
Ching‐Chuan Kuo Taiwan
Katarina Roos Sweden
Sang M. Chung United States
Alan Talevi Argentina
Patrick G. Swann United States
Michael A. Patane United States
Mark Namchuk United States
Tom Verhaeghe
Citations per year, relative to Tom Verhaeghe Tom Verhaeghe (= 1×) peers Mark Namchuk

Countries citing papers authored by Tom Verhaeghe

Since Specialization
Citations

This map shows the geographic impact of Tom Verhaeghe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Verhaeghe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Verhaeghe more than expected).

Fields of papers citing papers by Tom Verhaeghe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Verhaeghe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Verhaeghe. The network helps show where Tom Verhaeghe may publish in the future.

Co-authorship network of co-authors of Tom Verhaeghe

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Verhaeghe. A scholar is included among the top collaborators of Tom Verhaeghe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Verhaeghe. Tom Verhaeghe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Xu, Rui, Emmanuel Njumbe Ediage, Tom Verhaeghe, Jan Snoeys, & Lieve Dillen. (2024). Therapeutic siRNA Loaded to RISC as Single and Double Strands Requires an Appropriate Quantitative Assay for RISC PK Assessment. Nucleic Acid Therapeutics. 34(4). 199–210. 3 indexed citations
3.
Lagatie, Ole, Emmanuel Njumbe Ediage, Linda Batsa Debrah, et al.. (2021). Multimodal biomarker discovery for active Onchocerca volvulus infection. PLoS neglected tropical diseases. 15(11). e0009999–e0009999. 5 indexed citations
4.
Wauters, T., J. Buermans, Rob Haelterman, et al.. (2020). RF plasma simulations using the TOMATOR 1D code: a case study for TCV helium ECRH plasmas. Plasma Physics and Controlled Fusion. 62(10). 105010–105010. 5 indexed citations
5.
Pusecker, Klaus, et al.. (2015). Determination of tapentadol and tapentadol-O-glucuronide in human serum samples by UPLC–MS/MS. Journal of Chromatography B. 981-982. 40–47. 15 indexed citations
6.
Dirks‐Hofmeister, Mareike E., Tom Verhaeghe, Karel De Winter, & Tom Desmet. (2015). Creating Space for Large Acceptors: Rational Biocatalyst Design for Resveratrol Glycosylation in an Aqueous System. Angewandte Chemie International Edition. 54(32). 9289–9292. 38 indexed citations
7.
Verhaeghe, Tom, et al.. (2015). A structural classification of carbohydrate epimerases: From mechanistic insights to practical applications. Biotechnology Advances. 33(8). 1814–1828. 43 indexed citations
8.
9.
Ielasi, Francesco, Tom Verhaeghe, Tom Desmet, & Ronnie Willaert. (2014). Engineering the carbohydrate-binding site of Epa1p from Candida glabrata: generation of adhesin mutants with different carbohydrate specificity. Glycobiology. 24(12). 1312–1322. 12 indexed citations
10.
Vreese, Rob De, Tom Verhaeghe, Tom Desmet, & Matthias D’hooghe. (2013). Potent and selective HDAC6 inhibitory activity of N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes as novel sulfur analogues of Tubastatin A. Chemical Communications. 49(36). 3775–3775. 31 indexed citations
11.
Aerts, Dirk, Tom Verhaeghe, Bart I. Roman, et al.. (2011). Transglucosylation potential of six sucrose phosphorylases toward different classes of acceptors. Carbohydrate Research. 346(13). 1860–1867. 54 indexed citations
12.
Zannikos, Peter, Gerald Novak, Caiping Yao, et al.. (2009). Pharmacokinetics of carisbamate (RWJ‐333369) in healthy Japanese and Western subjects. Epilepsia. 50(8). 1850–1859. 3 indexed citations
13.
Hemeryck, Alex, Johan Monbaliu, Tom Verhaeghe, et al.. (2007). Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib. Cancer Chemotherapy and Pharmacology. 60(6). 777–787. 42 indexed citations
14.
Chien, Shuchean, Caiping Yao, Tom Verhaeghe, et al.. (2007). An Interaction Study Between the New Antiepileptic and CNS Drug Carisbamate (RWJ‐333369) and Lamotrigine and Valproic Acid. Epilepsia. 48(7). 1328–1338. 19 indexed citations
15.
Mannens, Geert, Jan Hendrickx, Shuchean Chien, et al.. (2006). The Absorption, Metabolism, and Excretion of the Novel Neuromodulator RWJ-333369 (1,2-Ethanediol, [1-2-Chlorophenyl]-, 2-carbamate, [ S ]-) in Humans. Drug Metabolism and Disposition. 35(4). 554–565. 35 indexed citations
16.
Yao, Caiping, Michael Gold, Jeffrey S. Nye, et al.. (2005). Steady‐State Pharmacokinetics of Galantamine Are Not Affected by Addition of Memantine in Healthy Subjects. The Journal of Clinical Pharmacology. 45(5). 519–528. 24 indexed citations
17.
Cohen, Steven J., James M. Gallo, Nancy Lewis, et al.. (2004). Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 53(6). 513–518. 7 indexed citations
18.
Verhaeghe, Tom, et al.. (2003). Development and validation of a liquid chromatographic–tandem mass spectrometric method for the determination of galantamine in human heparinised plasma. Journal of Chromatography B. 789(2). 337–346. 36 indexed citations
19.
Zhao, Qinying, et al.. (2002). Galantamine Pharmacokinetics, Safety, and Tolerability Profiles Are Similar in Healthy Caucasian and Japanese Subjects. The Journal of Clinical Pharmacology. 42(9). 1002–1010. 9 indexed citations
20.
Huang, Fenglei, et al.. (2002). Pharmacokinetic and Safety Assessments of Galantamine and Risperidone after the Two Drugs Are Administered Alone and Together. The Journal of Clinical Pharmacology. 42(12). 1341–1351. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark Namchuk Breakdown of academic impact, for papers by Alex Buko Breakdown of academic impact, for papers by Tuomo Laitinen Breakdown of academic impact, for papers by Naoko Kobayashi Breakdown of academic impact, for papers by Ching‐Chuan Kuo Breakdown of academic impact, for papers by Katarina Roos Breakdown of academic impact, for papers by Sang M. Chung Breakdown of academic impact, for papers by Alan Talevi Breakdown of academic impact, for papers by Patrick G. Swann Breakdown of academic impact, for papers by Michael A. Patane
Rankless by CCL
2026